Article Sidebar
Published:
Oct 15, 2022Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Effect of hyperbaric oxygen therapy on cognitive impairment after aneurysm subarachnoid hemorrhage
Abstract
Purpose: To evaluate the effect of hyperbaric oxygen therapy (HBOT) on cognitive impairment after aneurysm subarachnoid hemorrhage (aSAH).
Methods: The current study was carried out in a regional neurosurgical center in Taiyuan, Shanxi Province of China from January 2019 to September 2020. A total of 150 patients with persistent cognitive dysfunction at 3 months after aSAH onset were enrolled, which were randomly classified into group A (HBOT) and group B (control) via the random number table method. The outcome was evaluated by Montreal cognitive assessment (MoCA).
Results: There were no significant differences between group A and group B with regard to MoCA score and proportions of normal MoCA patients at 3 months after HBOT (p > 0.05). Both groups showed no significant differences in proportions of normal MoCA patients at 6 months after HBOT (p > 0.05). However, there were significant differences between group A and group B with MoCA score of patients at 6 months after HBOT (p < 0.05). There were also significant differences in MoCA score and proportions of normal MoCA patients at 9 months after HBOT.
Conclusion: HBOT alleviates cognitive impairment after aSAH, and thus may be used to manage cognitive impairment in patients after aSAH. However, further clinical trials are required prior to application in clinical practice.
